I. CALL TO ORDER

   a. The meeting was called to order at approximately 1:00 pm. Introductions were made by Committee members and staff.

   b. Mr. Citron reported there are no new conflicts of interest to declare.

   c. Approval of agenda and minutes presented by Dr. Origer. (pages 4 - 8)
Dr. Clark said the draft minutes did not reflect the concerns he voiced regarding the lack of disclosure of conflicts of interest from the CF Foundation and CF specialists and stated he would like to bring the Orkambi review back to the Committee again (using the same established review) to discuss whether this information would change the recommendations. Mr. Citron discussed the changes that have been made to the conflict of interest form.

**ACTION:** Motion, 2nd, All in Favor. Approved minutes as amended.

d. Department updates for OHA.

---

**II. DUR NEW BUSINESS**

a. Compound Drugs Drug Use Evaluation (pages 9 - 16)
   Ms. Ketchum presented the following drug use evaluation.
   1. Produce and publish educational documents.
   2. Approve proposed edits and quantity limits
   3. Approve cap upon paid amounts to require PA
   4. Perform and present policy evaluation in 2 years.

**ACTION:** Motion, 2nd, All in Favor. Approved.

b. Multi-vitamins Policy Evaluation (pages 17 - 35)
   Ms. Ketchum presented the multi-vitamin policy evaluation.
   Maintain current PA policy.

**ACTION:** Motion, 2nd, All in Favor. Approved.

c. Biologics Policy Evaluation (pages 36 - 58)
   Dr. Herink presented the Biologic policy evaluation.
   1. Continue to require PA for non-preferred biologics.
   2. Require PA for medical claims and auto-approve for cancer and MS diagnoses.
   3. Require PA on preferred biologics to promote step through appropriate DMARD therapy.

**ACTION:** Motion, 2nd, All in Favor. Approved.

---

**III. PREFERRED DRUG LIST NEW BUSINESS**

a. Pulmonary Arterial Hypertension Drug Class Update (pages 59 - 84)
   Dr. Gibler presented the following drug class update.
   1. Continue current PA criteria for oral/inhaled agents and parenteral agents.
   2. Add epoprostenol to the PMPDP and do not require PA.
   3. Evaluate comparative costs in executive session.

**Public Comment:**
George Yasutake, PharmD from Actelion gave public comment. 
Stuart O’Brochta from Gilead gave public comment.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

b. Phosphate Binders Class Update (pages 85 – 100) 
Dr. Gibler presented the following class update.

1. Maintain ferric citrate as non-preferred at this time and incorporate into current PA.
2. Continue to prefer at least one calcium-based phosphate binder and one non-calcium-based phosphate binder on the PMPDP.
3. Evaluate comparative costs in the executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

c. ADHD Drug Class Update (pages 101 – 114) 
Dr. Gibler presented the following class update.

1. Maintain QuilliChew ER and Adzenys XR-ODT as non-preferred on PMPDP based on limited evidence for safety and efficacy.
2. Approved proposed updates to the Safety Edit.
3. Evaluate comparative costs in executive session.

**Public Comment:**
Steven Fuchs, PharmD from Pfizer gave public comment.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

d. Sodium-glucose Co-transporter 2 Inhibitor Class Update (pages 115 – 125) 
Dr. Sentena presented the following class update.

1. Modify current PA criteria to allow use of SGLT2 inhibitors as a third-line option with metformin and sulfonylureas.

**Public Comment:**
Hiral Patel from AstraZeneca gave public comment.

**ACTION:** Motion to approve, 2nd, 1 in favor, 6 opposed, proposal rejected.

e. Calcium and Vitamin D Class Update (pages 126 – 143) 
Dr. Sentena presented the following class update.

1. Approve proposed PA criteria to restrict non-preferred vitamin D and calcium supplements to patients who are: pregnant; have a nutrient deficiency; have a diagnosis of osteopenia or osteoporosis; and patients 65 years of age or older who are at risk for falls
2. Allow dispensing of 90 day supply for pharmacy claims
3. Evaluate comparative costs in executive session

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

f. Opioid Reversal Agents Class Review (pages 144 – 154) 
Dr. Gibler presented the following class review.

1. Limit the quantity of naloxone to 2 units every 12 months without PA.
2. Refer clients who require naloxone more frequently for case management.
3. Evaluate comparative costs in executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

g. Insulin Degludec New Drug Evaluations (pages 155 – 182)
Dr. Sentena presented the following drug evaluation.

1. Maintain insulin degludec as non-preferred and subject to current PA criteria for insulin pens.
2. Make insulin degludec / aspart non-preferred and subject to current PA criteria when it comes to market.

**Public Comment:**
Shawn Hansen from Novo Nordisk gave public comment.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

h. Drug Class Literature Scans

1. Triptans (pages 183 – 195)
Dr. Herink presented the following drug class scan.

   a. No further research is needed at this time.
   b. Continue to include at least one agent available for each route of administration (oral, nasal, subcutaneous) and maintain current PA criteria.
   c. Evaluate comparative cost in executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

2. NSAIDs (pages 196 -205)
Dr. Herink presented the following drug class scan.

   a. No further research is needed at this time.
   b. Evaluate comparative costs in executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

3. Topical Antibiotics (pages 206 – 209)
Dr. Engen presented the following drug class scan.

   a. No further research is needed at this time.
   b. Evaluate comparative costs in executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

4. Topical Antiparasitics (pages 210 – 215)
Dr. Engen presented the following drug class scan.

   a. No further research is needed at this time.
   b. Evaluate comparative costs in executive session.

**ACTION:** Motion to approve, 2nd. All in favor. Approved.

I. Abbreviated Drug Reviews
Dr. Engen presented the following abbreviated drug reviews.
1. Eluxadoline (page 216)

   Require PA to restrict use to OHP-funded conditions.

**ACTION:** Motion, 2nd, All in Favor. Approved.

2. Flibanserin (page 217)

   Require PA to restrict use to OHP-funded conditions.

**ACTION:** Motion, 2nd, All in Favor. Approved.

3. Liraglutide (page 218)

   Require PA to restrict use to OHP-funded conditions.

**Public Comment:**
Shawn Hansen from Novo Nordisk gave public comment.

**ACTION:** Motion, 2nd, All in Favor. Approved.

4. Azelaic Acid (page 219)

   Require PA to restrict use to OHP-funded conditions.

**ACTION:** Motion, 2nd, All in Favor. Approved.

---

### IV. EXECUTIVE SESSION

### V. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session

a. Pulmonary Arterial Hypertension Class Update (pages 59 – 84)
   
   *ACTION:* recommend no changes to the PMPDP

   Motion, 2nd, All Favor. Approved.

b. Phosphate Binder Class Update and New Drug Evaluation (pages 85 – 100)

   *ACTION:* recommend no changes to the PMPDP

   Motion, 2nd, All Favor. Approved.

c. ADHD Class Update (pages 101 – 114)

   *ACTION:* recommend no changes to the PMPDP

   Motion, 2nd, All Favor. Approved.

d. Calcium & Vitamin D Class Update (pages 126 – 143)

   *ACTION:* recommend removing calcitriol and derivatives from the class and designate all other calcium and vitamin D products non-preferred on the PMPDP

   Motion, 2nd, All Favor. Approved.

e. Opioid Reversal Agent Class Review (pages 144 – 154)

   *ACTION:* recommend Naloxone auto-injector PDL – N, other formulations PDL – Y.

   Add class to the PMPDP
Motion, 2\textsuperscript{nd}, All Favor. Approved.

f. Triptans Drug Class Scan (pages 183 – 195)
   *\textbf{ACTION:} recommend no changes to the PMPDP
   Motion, 2\textsuperscript{nd}, All Favor. Approved.

g. NSAIDs Drug Class Scan (pages 196 – 205)
   *\textbf{ACTION:} recommend no changes to the PMPDP
   Motion, 2\textsuperscript{nd}, All Favor. Approved.

h. Topical Antibiotics Drug Class Scan (pages 206 – 209)
   *\textbf{ACTION:} recommend no changes to the PMPDP
   Motion, 2\textsuperscript{nd}, All Favor. Approved.

i. Topical Antiparasitics Drug Class Scan (pages 210 – 215)
   *\textbf{ACTION:} recommend no changes to the PMPDP, investigate a RetroDUR proposal
   Motion, 2\textsuperscript{nd}, All Favor. Approved.

---

\textbf{VI. ADJOURN}